SEPSIS Observational Cohort Study in Young Infants in Bangladesh
NCT ID: NCT04012190
Last Updated: 2022-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2083 participants
OBSERVATIONAL
2020-02-12
2022-10-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neonatal Sepsis, Evaluation, Bangladesh
NCT01333982
Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh
NCT00844337
Early-Onset Sepsis an NICHD/CDC Surveillance Study
NCT02410486
NeoAMR Observational Study in Neonatal Sepsis
NCT03721302
Prediction of Disease Severity in Young Children Presenting With Acute Febrile Illness in Resource-limited Settings
NCT04285021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A large body of evidence from inpatient neonatal populations, and the recent evidence from the Panigrahi et al. community trial in India, support an important role of intestinal dysbiosis in the pathogenesis of sepsis/SI in young infants. This mechanism may be particularly important in low- and middle-income countries in Africa and South Asia, where low-cost routine interventions to reduce the burden of SI (e.g., probiotics or synbiotics) could have an important impact on the burden of morbidity and mortality in young infants. However, there are limited data regarding the composition of the early postnatal microbiome in the general population of infants (rather than selected groups of preterm or hospitalized newborns) in South Asia and the role of the microbiome in modulating the risk of SI.
This observational study will generate new knowledge about the incidence and risk factors of SI, including the composition of the intestinal microbiome, in young infants (birth to 60 days of age) in Dhaka, Bangladesh. The aims of this study are to:
1. Estimate the incidence of SI in a facility-recruited cohort of Bangladeshi newborns during the first 60 days of life, and examine the sensitivity of the estimates to variations in SI case definitions;
2. Explore the associations between maternal-infant characteristics (e.g., mode of delivery, feeding practices, gestational age, antibiotic exposure) and the risk of SI in the first 60 days of life;
3. Estimate the absolute and relative stool abundances and age at initial colonization of Bifidobacterium longum subspecies (ssp.) infantis (B. infantis), Bifidobacterium longum ssp. longum (B. longum longum), Bifidobacterium breve (B. breve) and all bifidobacteria species combined during the first 60 days of life in Bangladeshi newborns, overall and within sub-groups defined by: mode of delivery, feeding practices, prior or current infant exposure to antibiotics, and whether there is colonization with the specific bacterial species or subspecies;
4. Explore the associations between maternal-infant characteristics (e.g., mode of delivery, feeding practices, gestational age, antibiotic use) and stool abundance (or age at initial colonization) of B. infantis, B. longum longum, and B. breve;
5. Estimate the association between stool abundance of B. infantis and SI in Bangladeshi newborns during the first 60 days of life;
6. Describe the composition, diversity, and stability of the microbiome in Bangladeshi newborns at multiple time-points during the first 60-days of life, and examine how the composition, diversity, and stability varies by mode of delivery and other maternal-infant and household characteristics;
7. In a facility-recruited cohort of Bangladeshi newborns, estimate the incidence proportions and/or incidence rates and/or prevalence of the following clinical outcomes up to 7 days, 28 days, 60 days of life, 3 months, and 6 months of age:
1. Hospitalization for any reason other than for routine postnatal care
2. Upper respiratory tract infections (URTI);
3. Lower respiratory tract infections (LRTI);
4. Acute or persistent diarrhea;
5. Significant neurological impairment or disability diagnosed by 6 months of age; and,
6. All-cause and non-injury-related mortality
8. Describe child anthropometry (length, weight, and head circumference) and standardized anthropometric indices (length-for-age, weight-for age, and weight-for-height, and head circumference-for-age z-scores) up to 60 days of age in a facility-recruited cohort of Bangladeshi newborns;
9. Estimate the cohort accrual rates of eligible newborns at two public maternal-child health care facilities in Dhaka, Bangladesh
Study personnel will conduct active and passive clinical surveillance and routine specimen collection (e.g. stool, nasal, skin and oral swabs etc.). Additional specimen collection may also be triggered in the event of physician-confirmed clinical severe infection, or if infants meet the case definition of LRTI (fast breathing with at least one of the following: cough, nasal congestion, or runny nose) or are hospitalized with diarrhea and/or vomiting.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infants delivered at a study hospital
* Orally feeding currently
* Informed consent by parent or guardian
* Intends to maintain residence within the defined catchment areas (upon discharge from hospital) until 60 days of age
Exclusion Criteria
* Death or major surgery considered to be highly probable within first week of life
* Major congenital anomaly of the gastrointestinal tract
* Maternal HIV infection and/or history of mother ever receiving anti-retroviral drug(s) for presumed HIV infection
* Current mechanical ventilation and/or cardiac support (e.g., inotropes) and/or administration/prescription of parenteral antibiotics
* Any prenatal or postpartum use of non-dietary probiotic supplement by mother (during current pregnancy)
* Any postnatal administration of non-dietary probiotic or prebiotic supplements to infant
* Enrolment of infant in any other clinical trial involving the administration of probiotics and/or prebiotics
* Resides in the same household as another infant previously enrolled in the study, or any study within the research platform, who is currently \<60 days of age; however, twins may all be enrolled simultaneously
* Multiple gestation for which the number of liveborn infants from the same pregnancy exceeds two (i.e., triplets or higher order multiples)
0 Days
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Child Health Research Foundation, Bangladesh
OTHER
Boston University
OTHER
McGill University
OTHER
University of California, San Diego
OTHER
The Hospital for Sick Children
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Roth
Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Roth
Role: PRINCIPAL_INVESTIGATOR
The Hospital for Sick Children
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternal Child Health Training Institute
Dhaka, , Bangladesh
Mohammadpur Fertility Services Training Centre
Dhaka, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1000063899
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.